Cryo-EM reveals “crown-like” structure of protein responsible for regulating blood flow
December 6, 2017
GRAND RAPIDS, Mich. (Dec. 6, 2017)—A team led by scientists at Van Andel Research Institute (VARI) has revealed for the first time the atomic-level structure of a promising drug target for conditions such as stroke and traumatic brain injury.
Called TRPM4, this protein is found in tissues throughout the body, including the brain, heart, kidney, colon and intestines, where it plays a major role in regulating blood flow via blood vessel constriction as well as setting the heart’s rhythm and moderating immune responses.
“Understanding the role TRPM4 plays in regulating circulation is vital, but for years research has been limited by a lack of insight about its molecular architecture,” said Wei Lü, Ph.D., an assistant professor at VARI and lead author on a study describing TRPM4’s structure, published today in Nature. “Our findings not only provide a detailed, atomic-level map of this critical protein, but also reveal completely unexpected facets of its makeup.”
TRPM4 is critically involved in regulating the blood supply to the brain, which comprises only about 2 percent of the body’s total weight yet receives 15 to 20 percent of its blood supply. Conditions that disrupt blood flow in the brain, such as stroke, traumatic brain injury, cerebral edema and hypertension, can have devastating consequences and are significant public health problems.
“Many safeguards exist in the brain’s circulatory system to protect against a sudden interruption in blood supply, one of which is TRPM4,” Lü said. “We hope that a better understanding of what this protein looks like will give scientists a molecular blueprint on which to base the design of more effective medications with fewer side effects.”
The structure of TRPM4 is markedly different from the other molecules in the TRP superfamily, a category of proteins that mediate responses to sensations and sensory stimuli, such as pain, pressure, vision, temperature and taste. Broadly known as ion channels, proteins like TRP nestle within cells’ membranes, acting as gatekeepers for chemical signals passing into and out of the cell.
Even within its own subfamily, which comprises eight molecules in total, TRPM4 appears to be wholly unique. Today’s publication represents the first atomic view of a member of the TRPM subfamily.
It reveals a crown-like structure, with the four peaks composing a large N-terminal domain—a hallmark of TRPM proteins. This region, found at the start of the molecule, is a major site of interaction with the cellular environment and other molecules in the body. On the opposite end of TRPM4, commonly called the C-terminal domain, Lü’s team found an umbrella-like structure supported by a “pole” and four helical “ribs”—characteristics that have never before been observed.
The findings were made possible by VARI’s state-of-the-art David Van Andel Advanced Cryo-Electron Microscopy Suite, which allows scientists to view some of life’s smallest components in exquisite detail. VARI’s largest microscope, the Titan Krios, is one of fewer than 120 in the world and is so powerful that it can visualize molecules 1/10,000th the width of a human hair.
In addition to Lü, VARI Assistant Professor Juan Du, Ph.D., also is an author on today’s paper. Paige A. Winkler, Ph.D., and Yihe Huang, Ph.D., both postdoctoral fellows in Lü’s lab, and Weinan Sun, Ph.D., a postdoctoral associate in the Spruston Lab at Howard Hughes Medical Institute Janelia Research Campus, are co-first authors.
ABOUT VAN ANDEL RESEARCH INSTITUTE
Van Andel Institute (VAI) is an independent nonprofit biomedical research and science education organization committed to improving the health and enhancing the lives of current and future generations. Established by Jay and Betty Van Andel in 1996 in Grand Rapids, Michigan, VAI has grown into a premier research and educational institution that supports the work of more than 360 scientists, educators and staff. Van Andel Research Institute (VARI), VAI’s research division, is dedicated to determining the epigenetic, genetic, molecular and cellular origins of cancer, Parkinson’s and other diseases and translating those findings into effective therapies. The Institute’s scientists work in onsite laboratories and participate in collaborative partnerships that span the globe. Learn more about
Van Andel Institute or donate by visiting www.vai.org. 100% to Research, Discovery & Hope®